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The STAMPEDE study evaluated the efficacy of 
abiraterone in high-risk patients with locally advanced 
or metastatic prostate cancer with concomitant andro-
gen-deprivation therapy (ADT). In total 1917 patients 
were randomly assigned (1:1) to a control group re-
ceiving only ADT or a study group receiving ADT in 
combination with abiraterone + prednisone (P, 5 mg 
daily). Both groups were well balanced for age and 
disease stage (52% comprised patients with metastatic 
disease, 20% patients with N+/NXM0, 28% patients 
with N0M0), 95% of patients were newly diagnosed, and 
median PSA was 53 ng/ml. Standard therapy included 
ADT used for at least two years. Prostate irradiation 
was used in all patients without nodal involvement and 
distal metastases, and in patients with N+ feature it was 
recommended. The duration of treatment was dependent 
on disease severity and possible radical radiotherapy. 
Patients with M1 and patients who did not undergo 
radical radiotherapy continued treatment to clinical, 
radiological, or biochemical (PSA) progression. The 
remaining patients were treated for up to two years or 
disease progression. The primary endpoint was overall 
survival (OS). After median follow-up of 40 months 
significant reduction (by 47%) of death relative risk in 
the abiraterone arm was indicated [HR = 0.63 (95% CI 
0.52–0.76; p = 0.115 × 10–7)]; three-year survival rate was 
83% (ADT + AA) vs. 76% (ADT). A statistically highly 
significant reduction (by 71%) of treatment failure rela-
tive risk [HR = 0.29 (95% CI 0.25–0.34)] was also noticed 
in the study group as compared to the control group. 
To the LATITUDE study, in total, 1199 patients 
were included with newly diagnosed (up to three months 
prior to randomisation), hormone-naive metastatic pros-
tate cancer. This population included high-risk patients 
with ECOG performance status 0–2 (at least two out of 
three risk factors: Gleason score ≥ 8, at least three bone 
metastases, measurable visceral metastases). Efficacy of 
early addition of AA + P to ADT was assessed. Simi-
larly to the STAMPEDE study, patients were randomly 
assigned to receive ADT + AA or ADT + placebo. 
The primary endpoints were OS and radiographic 
progression-free survival (rPFS). In the first interim 
analysis with a median follow-up of 30.4 months signifi-
cant reduction of death risk by 38% (HR = 0.62, 95% 
CI: 0.51–0.76, p < 0.0001), radiological progression by 
53%, and biochemical progression by 70% was shown. 
In view of such positive results the independent steer-
ing committee recommended unblinding the study and 
crossing patients to ADT+AA+P.
In the STAMPEDE study, grade 3–5 adverse events 
were observed in 33% and 47% of patients treated with 
ADT or ADT+AA, respectively.
The most common grade 3/4 adverse events reported 
in the LATITUDE study included: hypertension (20.3% 
of patients in study group vs. 10.0% in the control 
group), hypokalaemia (10.4% vs. 1.3%), increased ALT 
(5.5% vs. 1.3%), and AST (4.4% vs. 1.5%) level. 
Comment
Three years after presentation of the results of the 
CHAARTED study and two years after presentation of 
the STAMPED study results, which showed a significant 
reduction (by approximately 40%) in the relative death 
risk in patients with advanced, hormone-sensitive pros-
tate cancer after use of docetaxel in combination with 
ADT versus ADT alone, two additional studies have 
confirmed the efficacy of ADT when combined with 
abiraterone. Comparable effect of combined hormone 
therapy (ADT + AA) with chemo-hormone-therapy con-
firms an importance of intensive systemic treatment in 
prostate cancer patients with poor prognosis (mainly with 
M+ or N+ feature). Comparison of the effectiveness of 
both treatment strategies (chemo-hormone-therapy and 
combined hormone therapy) can only be indirect. Both 
therapy patterns have a similar effect on OS, with poten-
tially higher ADT + AA benefits in terms of delayed ra-
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diological and biochemical progression (which is logical 
considering long-term combined hormone therapy vs. six 
cycles of chemotherapy). Indirect analysis of side effects 
does not indicate a better safety profile for either of the 
aforementioned therapeutic options. Therefore, it should 
be stated that abiraterone + ADT could be considered 
as a further option for treating hormone-naive patients 
with advanced prostate cancer, and possible use of such 
a treatment depends on the general status of the patient, 
the patient’s preferences, and reimbursement. 
Sources
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Capecitabine — a new standard of adjuvant treatment for patients with biliary 
tract cancer — results from the BILCAP study
Between 2006 and 2014, in total 447 patients with 
biliary cancer (CCA, cholangiocarcinoma) or gallbladder 
cancer (including patients after hepatic and pancreatic 
resection) with normal drainage of the biliary tract, and 
in good performance status (ECOG ≤ 2), were included 
into the BILCAP study. Patients were randomly assigned 
(1:1) to capecitabine at the dose of 1250 mg/m2 (up to 
eight cycles) on days 1–14 of the 21-day cycle (n = 223) 
or observation (n = 224). The study included patients 
from 44 centres in the UK. The primary endpoint was 
overall survival time (OS) in the intention-to-treat 
(ITT) population. Preliminary analysis was performed 
after a 24-month follow-up. Median patients’ age was 
63 years. The performance status of the majority of 
patients (97%) according ECOG scale was 0–1. Local-
isation of primary lesion was as follows: liver — 19%, 
hepatic hilus — 28%, extrahepatic location — 35%, and 
gallbladder (with muscular layer infiltration) — 18%. 
R0 resections were performed in 62% of patients and 
R1 resection in 38%. 46% of patients were node-neg-
ative. Over 80% of living patients were observed for at 
least 36 months. Based on the analysis performed in the 
ITT population (n = 447), median OS was 51 months 
(95% CI 35–59) in the group receiving capecitabine in 
the adjuvant setting as compared to 36 months (95% CI 
30–45) in the group undergoing only observation (con-
trol group) [HR=0.80 (95% CI 0.63–1.04; p = 0.097)]. 
Based on per-protocol analysis (n = 210, control group 
n = 220), the median OS was 53 months (95% CI 40–NR) 
in the study group and 36 months (95% CI 30–44) in the 
control group [HR 0.75 (95% CI 0.58–0.97; p = 0.028)]. 
Median relapse-free time (RFT) in the ITT population 
was 25 months (95% CI 19–37) in the study group and 
18 months (95% CI 13–28) in the control group. The 
toxicity profile as regards grade 3 and 4 adverse events 
was consistent with expectations. 
Comment
The results of the BILCAP study finally reinforce 
the new, long-awaited standard for management of 
patients with biliary tract cancer after surgery with 
radical intention. Until now, many patients, mainly 
with N+ feature, received adjuvant chemotherapy 
based on a combination of gemcitabine and cisplatin 
as a standard of palliative treatment in patients with 
advanced biliary cancer. Per protocol analysis showed 
significant reduction of relative death risk by 25% in 
patients receiving capecitabine as compared to obser-
vation alone. This is very important information high-
lighting the importance of proper patient qualification 
to adjuvant treatment. It has been shown in patients 
with pancreatic cancer, receiving adjuvant treatment 
in the ESPAC-3 study, that the efficacy of adjuvant 
therapy is not dependent on rapid onset of treatment, 
but rather on administration of full-dose scheduled 
treatment. Thus, with regard to available data from the 
BILCAP study (ITT vs. per-protocol analysis), it should 
be assumed that the key to achieving the presumed 
adjuvant chemotherapy effect is to start treatment 
when the patient’s performance status makes possible 
to complete a planned six-month chemotherapy with 
capecitabine. 
Sources
1. Primrose JN, Fox R, Palmer DH, et al. Adjuvant capecitabine for 
biliary tract cancer: The BILCAP randomized study. J Clin Oncol. 
2017; 35 (suppl; abstr 4006); http://abstracts.asco.org/199/Abst-
View_199_186869.html.
2. Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of 
adjuvant chemotherapy after definitive surgery for ductal adenocar-
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J Clin Oncol. 2014; 32: 504–512.
73
Monika Dudzisz-Śledź, Piotr Wysocki, Oncology courier
ASCO 2017: Short-term, three-month adjuvant chemotherapy — a potential new 
standard in adjuvant treatment of some patients with stage III colorectal cancer 
— IDEA analysis
On 4th June at the plenary session of the ASCO 
2017 Congress the results of a prospective, combined 
analysis of six concurrent phase III clinical trials on 
the duration of adjuvant treatment of patients with 
colorectal cancer were presented. The SCOT, TO-
SCA, Alliance/SWOG 80702, IDEA France (GER-
COR/PRODIGE), ACHIEVE, and HORG studies 
evaluated whether three-month adjuvant treatment in 
patients with stage III colorectal cancer (13% T1–2, 
66% T3, 21% T4, 72% N1, 28% N2) with oxalipla-
tin-based protocols (FOLFOX or XELOX) is non-in-
ferior as compared to the same standard adjuvant 
treatment administered for six months. The primary 
endpoint was disease-free survival (DFS). The study 
involved 12,834 patients included in the six afore-
mentioned studies in 12 countries between 2007 and 
2015. After a median follow-up of 39 months, there 
were 3263 DFS events. The three-year disease-free 
survival rate was 74.6% for three-month adjuvant 
treatment and 75.5% for six-month adjuvant treatment 
[HR = 1.07 (95% CI 1.00–1.15)], whilst in the group of 
patients treated with FOLFOX regimen HR for DFS 
for comparison three vs. six months was 1.16 (95% CI 
1.06–1.26) and for treatment with XELOX regimen 
0.95 (95% CI 0.85–1.06). HR for DFS for comparison 
three vs. six months was 1.01 (95% CI 0.90–1.12) in pa-
tients with stage T1–3 N1 and 1.12 (95% CI 1.03–1.23) 
for patients with cancer T4 or N2. Neurotoxicity of 
at least grade 3 according to the CTCAE criteria was 
observed more frequently in patients treated for six 
months (16% vs. 3% for FOLFOX, 9% vs. 3% for 
XELOX, p < 0.0001).
Comment
The results of the IDEA analysis are changing the 
standard of care for most patients with stage III colon 
cancer. For the first time, it has been unequivocally 
shown that three-month adjuvant doublet chemotherapy 
is not only as effective as standard six-month treatment, 
but also significantly less toxic. The ability to reduce (by 
more than 70%) the risk of neurotoxicity while main-
taining high efficacy of adjuvant therapy is an enormous 
achievement. The perspective of good quality of life, 
in the context of significant reductions in the risk of 
relapse after oxaliplatin-based doublet chemotherapy, 
should translate into more effective adjuvant therapy for 
patients who have been treated suboptimally, mainly due 
to their age and therapy duration. However, it should 
be highlighted that three-month adjuvant chemotherapy 
is not a treatment dedicated to all patients in stage III 
colorectal cancer. It should be used only in patients with 
pT1–3 and pN1 feature. Taking into account all current 
literature data — MOSAIC, NO16968, and IDEA 
studies, XELOX seems to be an optimal three-month 
adjuvant chemotherapy regimen for patients with stage 
III colon cancer. 
Source
1. Shi Q, Sobrero AF, Shields AF, et al. Prospective pooled analysis of 
six phase III trials investigating duration of adjuvant (adjuv) oxalipla-
tin-based therapy (3 vs 6 months) for patients (pts) with stage III colon 
cancer (CC): The IDEA (International Duration Evaluation of Adjuvant 
chemotherapy) collaboration. J Clin Oncol 2017; 35 (suppl; abstr 
LBA1); http://abstracts.asco.org/199/AbstView_199_188616.html.
ASCO 2017: Olaparib — a new therapeutic option for patients with HER2-negative 
metastatic breast cancer and BRCA mutation — OlympiAD, phase III tiral
During the plenary session of the ASCO 2017 Con-
gress and in the New England Journal of Medicine the 
results of the OlympiAD (NCT02000622) study were 
presented, evaluating the efficacy of oral PARP inhib-
itor, olaparib, in patients with metastatic HER2-nega-
tive breast cancer, being BRCA mutation carriers. An 
open-label phase III clinical study enrolled 302 patients 
who had previously undergone no more than two pal-
liative chemotherapy lines (median age 44 years, 71% 
of patients previously treated with chemotherapy, 28% 
with platinum-based chemotherapy, and 50% with 
triple-negative phenotype). Patients were randomly 
assigned (2:1) to receive olaparib (300 mg twice daily, 
orally, n = 205) or chemotherapy (depending on the 
investigator choice: capecitabine 2500 mg/m2 orally on 
days 1–14 of a 21-day cycle or vinorelbine 30 mg/m2 in-
travenously on days 1 and 8 of a 21-day cycle, or eribulin 
1.4 mg/m2 intravenously on days 1 and 8 of a 21-day 
cycle, n = 91). Treatment was continued to objective 
progression (RECIST 1.1) or unacceptable toxicity. The 
primary endpoint was progression-free survival (PFS) 
assessed within independent blinded central evaluation. 
During the first interim analysis (median follow-up 
of 14 months) olaparib significantly reduced progres-
sion risk by 42% in the study group, prolonging time to 
progression (TTP) by approximately three months (HR 
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0.58, 95% CI 0.43–0.80; p = 0.0009; median PFS — 7.0 and 
4.2 months, respectively). Objective response rate (ORR) 
in the olaparib group was 59.9% compared to 28.8% in the 
chemotherapy arm. Time to second progression was also 
prolonged (HR 0.57, 95% CI 0.40–0.83), and quality of 
life (assessed by the EORTC-QLQ-C30 questionnaire) of 
patients treated with olaparib was significantly (p = 0.0035) 
improved as compared to patients receiving chemotherapy. 
The safety profile of olaparib was similar to that observed 
in earlier studies with this drug. Adverse events of at least 
grade 3 were reported in 36.6% of patients receiving 
olaparib and 50.5% of patients undergoing chemotherapy. 
Comment
Approximately 3% of breast cancers occur in patients 
with BRCA mutations (in the Polish population mainly 
BRCA1). In carriers of such mutations breast cancers 
develop at a much younger age, are more aggressive, 
and most often are triple-negative. Thus, the treatment 
of patients with breast cancer developing on the basis of 
BRCA gene mutation is much more difficult because until 
now chemotherapy has been the only option of systemic 
therapy in clinical practice. BRCA mutation damages 
one of the two basic DNA repair mechanisms in a cell. 
Therefore, survival of a tumour cell with a non-function-
al BRCA protein and with continuous DNA damaging 
depends on proper functioning of PARP-dependent 
repair mechanisms poly (ADP-ribose) polymerase 
(PARP). PARP inhibitor leads to death of cancer cells 
by inhibiting critical DNA repair mechanism in BRCA 
mutant cell. Efficacy of olaparib has already been 
demonstrated in patients with ovarian cancer with BRCA 
mutation. The results of the OlympiAD study reinforce 
the role of olaparib as the first targeted therapy for 
patients with breast cancer developing on the basis of 
BRCA hereditary mutation. This is particularly import-
ant in the context of triple-negative tumours, which in 
the Polish population account for the vast majority of 
cancers developing in carriers of the BRCA1 mutation. 
Sources
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(gBRCAm). J Clin Oncol. 2017; 35 (suppl; abstr LBA4); http://abstracts.
asco.org/199/AbstView_199_186720.html.
2. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer 
in patients with a germline BRCA mutation. N Engl J Med. 2017 Jun 
4; DOI: 10.1056/NEJMoa1706450.
ASCO 2017: Single-dose radiotherapy is an effective treatment in patients with 
metastatic spinal canal compression (MSCC) — SCORAD study
The SCORAD study compared the efficacy of 
single-dose radiation with standard treatment in 
patients with spinal compression due to metastat-
ic cancer (metastatic spinal canal compression, 
MSCC). Between 2008 and 2016 in total 688 patients 
at 43 centres in the UK and four in Australia were 
randomly assigned to irradiation with a single 8-Gy 
fraction (n = 345) or to irradiation with 20-Gy dose 
in five fractions (n = 343). Patients with prostate 
cancer (44%), lung cancer (18%), gastrointestinal 
cancers (11%), and breast cancer (11%) were in-
volved in the study. There was comparable efficacy 
and safety of both radiotherapy regimens. The dif-
ference in median OS was not significant and median 
OS reached 12.4 weeks in the group with a single 
dose of RT vs. 13.7 weeks in the group receiving five 
fractions [HR = 1.02 (95% CI 0.86–1.21), p = 0.81). 
Tolerability of treatment was also similar — the in-
cidence of grade 3 and 4 adverse events was 20.6% 
in patients after one fraction and 20.4% in patients 
treated with standard irradiation; grade 1 and 2 ad-
verse events occurred less commonly in patients with 
one dose of RT (51.0% vs. 56.9%).
Comment
The continuously increasing population of patients 
with chronic, generalised cancers is resulting in a growing 
number of patients requiring local palliative oncological 
treatment. Extended indications to radiotherapy, and 
an increasing number of procedures and patients re-
quiring irradiation are an increasingly serious problem, 
particularly in the context of relatively slow growth in the 
number of specialists and insufficient development of 
infrastructure and equipment. Spinal canal compression 
is an emergency in oncology that requires urgent local 
treatment. Possible five-fold reduction in the duration of 
irradiation (from five days to one day) not only improves 
patients’ comfort, but at the same time, without worsening 
local effects, improves the availability of radiotherapy for 
other patients requiring this type of cancer treatment. 
Source
1. Hoskin P, Misra V, Hopkins K, et al. SCORAD III: Randomized nonin-
feriority phase III trial of single-dose radiotherapy (RT) compared to 
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